Evidence map›Paper›PMID 17710514›Full record

ArticlePharmaceutical research2008

The role of permeability in drug ADME/PK, interactions and toxicity--presentation of a permeability-based classification system (PCS) for prediction of ADME/PK in humans.

Urban Fagerholm

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Natural Epithelial Barrier Integrity Enhancers-Gels (Basel, Switzerland) · 2024
    Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Urban FagerholmClinical Pharmacology, AstraZeneca R&D Södertälje, S-151 85, Södertälje, Sweden. urban.fagerholm@astrazeneca.com

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe objective was to establish in vitro passive permeability (Pe) vs in vivo fraction absorbed (fa)-relationships for each passage through the human intestine, liver, renal tubuli and brain, and develop a Pe-based ADME/PK classification system (PCS). MATERIALS AND

methodsPe- and intestinal fa-data were taken from an available data set. Hepatic fa was calculated based on extraction ratios of the unbound fraction of drugs (with support from animal in vivo uptake data). Renal fa (reabsorption) was estimated using renal pharmacokinetic data, and brain fa was predicted using animal in vitro and in vivo brain Pe-data. Hepatic and intestinal fa-data were used to predict bile excretion potential.

resultsRelationships were established, including predicted curves for bile excretion potential and minimum oral bioavailability, and a 4-Class PCS was developed: I (very high Pe; elimination mainly by metabolism); II (high Pe) and III (intermediate Pe and incomplete fa); IV (low Pe and fa). The system enables assessment of potential drug-drug transport interactions, and drug and metabolite organ trapping.

conclusionsThe PCS and high quality Pe-data (with and without active transport) are believed to be useful for predictions and understanding of ADME/PK, elimination routes, and potential interactions and organ trapping/toxicity in humans.

Indexed as

Models, BiologicalPharmacokineticsToxicologyAdministration, OralAnimalsBileBiological AvailabilityBrainComputer SimulationDrug InteractionsHumansIntestinal AbsorptionIntestinal MucosaKidney TubulesLiverPermeabilityPharmaceutical Preparations

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.